interval appendectomy
Procedureinterval appendectomy at 2 to 3 months after the initial non-operative treatment
NCT Number: NCT04634448
Complicated and uncomplicated appendicitis follow different epidemiological trends also suggesting different pathophysiology behind these two different forms of appendicitis. In 3-10% of patients complicated acute appendicitis is enclosed by formation of a circumscribed periappendicular abscess. The clinically established practice of antibiotic therapy and drainage, if necessary, has been shown safe and effective, allowing the acute inflammatory process to subside in more than 90% of cases without surgery. The need of subsequent interval appendectomy has been questioned with appendicitis recurrence risk varying between 5-26%.
During trial enrollment in our randomized Peri-APPAC trial based on the interim analysis results with 17% appendiceal tumor rate in the study population, the trial was prematurely terminated based on ethical concerns. All the follow-up group patients were re-evaluated and surgery was offered and recommended to all follow-up group patients. After this assessment and additional appendectomies, two more tumors were diagnosed resulting in neoplasm rate of 20% in the whole study group all diagnosed in patients over 40 years and the neoplasm rate in patients over 40 years was 29%.
Based on high appendiceal tumor rate in patients over 40 years, the appendiceal neoplasm rate needs to be further evaluated in prospective patient cohorts undergoing interval appendectomy as interval appendectomy is generally well tolerated and obliterates the risk of missing a possible tumor. In a recent systematic review of retrospective cohort studies with 13.244 acute appendicitis patients the overall appendiceal tumor rate was 1% after appendectomy, but in patients presenting with appendiceal inflammatory mass the neoplasm rate varied from 10% to 29%.
This nationwide prospective multicenter cohort study is designed to assess the prevalence of appendiceal tumors associated with a periappendicular abscess. All consecutive patients presenting with a periappendicular abscess are recommended to undergo interval appendectomy after initial conservative treatment with antibiotic therapy and drainage, if necessary. All patients older than 35 years will undergo laparoscopic interval appendectomy at 2 to 3 months and this is also recommended for the patients between 18 and 35 years of age. Asymptomatic patients under 35 years not willing to undergo interval appendectomy, will undergo a follow-up MRI at 1 year after the initial non-operative treatment.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Complicated and uncomplicated appendicitis follow different epidemiological trends also suggesting different pathophysiology behind these two different forms of appendicitis. In 3-10% of patients complicated acute appendicitis is enclosed by formation of a circumscribed periappendicular abscess. The clinically established practice of antibiotic therapy and drainage, if necessary, has been shown safe and effective, allowing the acute inflammatory process to subside in more than 90% of cases without surgery. The need of subsequent interval appendectomy has been questioned with appendicitis recurrence risk varying between 5-26%.
During trial enrollment in our randomized Peri-APPAC trial, the high incidence of appendiceal tumors in the study population alarmed the researchers. Based on the interim analysis results with 17% appendiceal tumor rate in the study population, the trial was prematurely terminated based on ethical concerns. All the follow-up group patients were re-evaluated and surgery was offered and recommended to all follow-up group patients. After this assessment and additional appendectomies, two more tumors were diagnosed resulting in neoplasm rate of 20% in the whole study group all diagnosed in patients over 40 years and the neoplasm rate in patients over 40 years was 29%.
Based on high appendiceal tumor rate in patients over 40 years, the appendiceal neoplasm rate needs to be further evaluated in prospective patient cohorts undergoing interval appendectomy as interval appendectomy is generally well tolerated and obliterates the risk of missing a possible tumor. In a recent systematic review of retrospective cohort studies with 13.244 acute appendicitis patients the overall appendiceal tumor rate was 1% after appendectomy, but in patients presenting with appendiceal inflammatory mass the neoplasm rate varied from 10% to 29%.
This nationwide prospective multicenter cohort study is designed to assess the prevalence of appendiceal tumors associated with a periappendicular abscess. All of the study hospitals will have a common clinical protocol of recommending interval appendectomy to all patients presenting with a periappendicular abscess after initial conservative treatment with antibiotic therapy and drainage, if necessary. Considering the high rate of appendiceal neoplasms, all patients older than 35 years will undergo laparoscopic interval appendectomy at 2 to 3 months after the successful initial non-operative treatment and this is also recommended for the patients between 18 and 35 years of age. Asymptomatic patients under 35 years not willing to undergo interval appendectomy, will undergo a follow-up MRI at 1 year after the initial non-operative treatment.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
interval appendectomy at 2 to 3 months after the initial non-operative treatment
follow-up MRI at 1 year for asymptomatic patients under 35 years of age not wanting to undergo surgery
Time frame: 2-3 months (interval appendectomy)
The Prevalence of Appendiceal Tumours in Patients Presenting With a Periappendicular Abscess - A Nationwide Prospective Cohort Study
Time frame: Day 0 (on primary admission)
All patients
Time frame: Day 0 (on primary admission)
All patients
Time frame: Day 0 (on primary admission)
All patients
Time frame: Day 0 (on primary admission) up to 3-5 days (discharge from the hospital)
CRP
Time frame: Day 0 (on primary admission) up to 3-5 days (discharge from the hospital)
leuk
Time frame: Day 0 (on primary admission) up to 3-5 days (discharge from the hospital)
neutr
Time frame: Day 0 (on primary admission) up to 3-5 days (discharge from the hospital)
Hb
Time frame: Day 0 (on primary admission) up to 3-5 days (discharge from the hospital)
Krea
Time frame: Day 0 (on primary admission) up to 3-5 days (discharge from the hospital) and up to 1 year, if no interval appendectomy
CEA
Time frame: Day 0 (on primary admission) up to 3-5 days (discharge from the hospital)and up to 1 year, if no interval appendectomy
Cg-A
Time frame: Day 0 and up to one week
All patients, treatment details
Time frame: 2 weeks to 2 months prior to planned interval appendectomy
In both intervention groups
Time frame: At 3 months
Interval appendectomy patients
Time frame: at the time of surgery
Clavien-Dindo classification, interval appendectomy group
Time frame: up to 2 years
All patients both at primary treatment, interval appendectomy and follow-up
Time frame: at 1 year
In case the patient does not under interval appendectomy
Time frame: at 1 year
Follow-up MRI patients
Time frame: at 1 year
Follow-up MRI patients
Time frame: up to 10 years
Follow-up with MRI patients
Contact information is provided by the study sponsor or research team.
Turku University Hospital
Other Gov
The Prevalence of Appendiceal Tumours in Patients Presenting With a Periappendicular Abscess - A Nationwide Prospective Cohort Study
Acronym: PeriAPPAC-T
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05734430
Adenocarcinoma, Adenocarcinoma, Mucinous
Nashville, Tennessee, United States
View Trial DetailsNCT04755179
Appendicitis, Appendicitis Perforated
Alkmaar, Netherlands
View Trial DetailsNCT07688109
Appendicitis, Cecal Diseases
Sanaa, Yemen
View Trial DetailsNCT06943456
Appendicitis, Cecal Diseases
View Trial Details